# WEE1 kinase inhibitor program

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/wee1-kinase-inhibitor-program
Canonical HTML page: https://getbiobrief.com/entity/wee1-kinase-inhibitor-program

## Recent coverage (1 stories)

### Aprea's 28 Issued Patents Shield WEE1/ATR Pipeline as APR-1051 Advances
2026-08-29 02:23:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aprea's expanded patent estate covers its DNA damage response pipeline, including lead WEE1 inhibitor APR-1051 in Phase 1. The IP package protects biomarker-defined cancer programs targeting WEE1 and ATR kinases.
Full story: https://getbiobrief.com/story/aprea-wee1-atr-inhibitor-pipeline-apr-1051-patent-protection

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.